Impact of Hearing Loss and Tinnitus in Cancer Survivors

听力损失和耳鸣对癌症幸存者的影响

• 批准号: 9362517
• 负责人: CHRISTINE A. MIASKOWSKI
• 金额: $ 90.44万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9362517
• 关键词: Address; Adult; Applications Grants; Auditory; Auditory system; Awareness; Blood specimen; Breast; Breast Cancer survivor; Cancer Survivor; Cancer Survivorship; Characteristics; Cognitive; Cyclophosphamide; Data; Data Analyses; Diagnosis; Ear; Enrollment; Etiology; Evaluation; Funding; Future; Genomics; Grant; Growth; Guidelines; Gynecologic Oncology Group; Gynecology; Head; Head and Neck Cancer; Hearing; Impairment; Intervention; Intervention Studies; Literature; Long-Term Effects; Long-Term Survivors; Lower Extremity; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of testis; Measures; Molecular; National Comprehensive Cancer Network; Nervous system structure; Pain; Patients; Pharmaceutical Preparations; Phenotype; Platinum; Platinum Compounds; Population; Quality of life; Recruitment Activity; Reporting; Research; Research Project Summaries; Review Literature; Sampling; Severities; Survivors; Testing; Time; Tinnitus; Toxic effect; United States; Upper Extremity; Work; active method; cancer therapy; chemotherapy; chemotherapy induced neuropathy; depressive symptoms; functional status; gastrointestinal; hearing impairment; improved; neurotoxic; neurotoxicity; oncology; pediatric patients; taxane

Project Summary Research on hearing loss and tinnitus associated with neurotoxic chemotherapy (CTX) has focused primarily on pediatric patients. In adults, the extremely limited amount of work has reported on hearing loss and tinnitus associated with the administration of platinum compounds primarily in patients undergoing active treatment for testicular or head and neck cancer. However, no studies have systematically evaluated hearing loss and tinnitus in cancer survivors who received a platinum and/or a taxane compound for breast, gastrointestinal (GI), gynecological (GYN), or lung cancer. Given that these diagnoses are the four most common cancers in adults and platinum and taxane compounds are the mainstay of treatment for these cancers, an evaluation of the severity and impact of hearing loss and tinnitus from these drugs is a significant issue for cancer survivorship. Recently, we completed enrollment in our ongoing R01 (CA151692) that is focused on an evaluation of differences in phenotypic and molecular characteristics of chemotherapy-induced neuropathy (CIN) in 400 survivors with CIN and 200 survivors without CIN. In preliminary analyses data from 310 patients with CIN, 49.0% reported hearing loss and/or tinnitus (i.e., 16.1% reported only hearing loss, 12.3% reported only tinnitus, and 20.6% reported both hearing loss and tinnitus). In contrast, in the 79 patients without CIN, 72.2% did NOT report hearing loss or tinnitus. Given that almost 50% of the patients with CIN reported some form of auditory toxicity, this grant application will focus on a more detailed characterization of hearing loss and tinnitus to determine their underlying mechanisms and impact of survivors' level of function and QOL. Blood samples will be collected and stored for future genomic analyses. The primary aims of this study, in a sample of survivors who received a platinum and/or a taxane compound and are classified into one of four groups (i.e., 1) survivors without CIN, hearing loss, and tinnitus; 2) survivors with CIN and without hearing loss and tinnitus; 3) survivors with CIN and only hearing loss; and 4) survivors with CIN and both hearing loss and tinnitus), are to: 1) evaluate for differences among the four groups in subjective and objective characteristics of hearing loss; 2) evaluate for differences among the four groups in subjective characteristics of tinnitus; and 3) evaluate for differences among the four groups in functional status, cognitive status, financial toxicity, and QOL. The secondary aim of this study is to evaluate for changes over time in subjective and objective measures of CIN in the survivors with CIN who were evaluated in CA151692. The information on etiology and severity, as well as on the impact of these two types of auditory toxicity will be used to plan intervention studies to improve hearing, reduce the impact of tinnitus, and assist cancer survivors to adapt to the long term effects of hearing loss and tinnitus.

项目摘要 与神经毒性化学疗法（CTX）相关的听力丧失和耳鸣的研究已有 主要专注于儿科患者。在成年人中，工作量极为有限 报道了与铂化合物给药相关的听力损失和耳鸣 主要是在接受睾丸或头颈癌的患者中。 但是，没有研究对癌症的听力损失和耳鸣进行系统评估 接受乳白铂和/或紫杉烷化合物的幸存者，胃肠道（GI）， 妇科（GYN）或肺癌。鉴于这些诊断是最常见的四个 成人，铂和紫杉烷化合物的癌症是这些治疗的支柱 癌症，对这些药物的听力损失和耳鸣的严重程度和影响的评估 对于癌症生存是一个重要的问题。最近，我们完成了正在进行的 R01（CA151692）的重点是评估表型和分子的差异 400个CIN幸存者和200 没有Cin的幸存者。在初步分析中，来自310例CIN患者的数据，有49.0％报告 听力损失和/或耳鸣（即16.1％报告仅听证会，有12.3％的人报告只报告耳鸣， 和20.6％的人报告听力损失和耳鸣）。相反，在没有CIN的79例患者中， 72.2％没有报告听力损失或耳鸣。鉴于几乎50％的CIN患者 报告了某种形式的听觉毒性，该赠款应用程序将集中在更详细的 听力损失和耳鸣的表征，以确定其潜在机制和 幸存者的功能水平和QoL的影响。将收集并存储血液样本 未来的基因组分析。这项研究的主要目的是在收到的幸存者样本中 铂和/或紫杉烷化合物，分为四组之一（即1）之一 没有CIN，听力损失和耳鸣的幸存者； 2）幸存者有CIN，没有听力损失 和耳鸣； 3）CIN的幸存者，只有听力损失； 4）与Cin和Cin一起幸存者 听力损失和耳鸣）是：1）评估主观四组之间的差异 听力损失的客观特征； 2）评估四组之间的差异 在耳鸣的主观特征中； 3）评估四组之间的差异 功能状况，认知状况，财务毒性和质量检查。这项研究的次要目的是 评估幸存者CIN的主观和客观度量中随着时间的变化的变化 与CIN在CA151692中进行了评估。有关病因和严重性以及 关于这两种类型的听觉毒性的影响，将用于计划干预研究 改善听力，减少耳鸣的影响，并帮助癌症幸存者适应长期 听力损失和耳鸣的术语影响。